Live Breaking News & Updates on Myelofibrosis Symptom Assessment

Stay updated with breaking news from Myelofibrosis symptom assessment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TP-3654 Demonstrates Favorable Tolerability, Early Clinical Activity in R/R Myelofibrosis

The oral selective PIM1 kinase inhibitor TP-3654 appeared to be well tolerated and to show early signals of spleen volume reduction, symptom improvement, and correlating cytokine reductions in patients with relapsed or refractory myelofibrosis, according to preliminary data. ....

North Carolina , United States , Duke University Medical Center , Dynamic International Prognostic Scoring System , Myelofibrosis Symptom Assessment , Pim1 Kinase Inhibitor , Tp 3654 , Phase 1 2 Tp 3654 102 Study ,

Momelotinib Found Superior to Danazol for the Treatment of Myelofibrosis

Clinically significant improvements in symptoms, anemia, and spleen response were achieved in myelofibrosis with momelotinib, compared with danazol. ....

Myelofibrosis Symptom Assessment ,

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

GSK plc (LSE/NYSE: GSK) today announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patie ....

United States , United Kingdom , Hesham Abdullah , American Society Of Hematology , European Medicines Agency , Global Head Of Oncology Development , Drug Administration , London United Kingdom , Total Symptom Score , Transfusion Independence , Splenic Response Rate , American Society , Annual Meeting , Senior Vice President , Global Head , Oncology Development , Myelofibrosis Symptom Assessment , New Drug Application , Marketing Authorisation Application , Medical Specialties , Blood Transfusion , Clinical Endpoint ,

GSK momelotinib receives US FDA acceptance for New Drug Application

GSK momelotinib receives US FDA acceptance for New Drug Application ....

United States , American Society Of Clinical Oncology Annual Meeting , Sierra Oncology Inc , European Hematology Association , Drug Administration , New Drug Application , Prescription Drug User Fee Act , Total Symptom Score , Transfusion Independence , Splenic Response Rate , Clinical Oncology Annual Meeting , Myelofibrosis Symptom Assessment , Sierra Oncology ,

US FDA accepts new drug application for GSKs momelotinib for the treatment of myelofibrosis

Regulatory submission included data from the pivotal MOMENTUM phase III clinical trial that met all primary and key secondary efficacy endpoints. ....

United States , American Society Of Clinical Oncology Annual Meeting , Sierra Oncology Inc , European Hematology Association , Drug Administration , New Drug Application , Prescription Drug User Fee Act , Total Symptom Score , Transfusion Independence , Splenic Response Rate , Clinical Oncology Annual Meeting , Myelofibrosis Symptom Assessment , Sierra Oncology , Hematol Oncol , Myelofibrosis Related Anemia , Emerging Therapeutic , Merger And Acquisition , Chemical Compounds , Janus Kinase Inhibitor , Organic Compounds ,